← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Humacyte, Inc.
Research Triangle Park, NC
$6,161,903
Total funding
5
Grants
Funding over time
peak $1.7M · FY2010–16$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$6,161,903 · 5
By mechanism
R44$4,137,321 · 2
N01$1,570,756 · 1
R43$453,826 · 2
Investigators at Humacyte, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Novel Manufacturing Processes for Tissue Engineered Vascular Grafts$998,367
R44 · FY2013 · HL
Novel Manufacturing Processes for Tissue Engineered Vascular Grafts$981,567
R44 · FY2014 · HL
Novel Manufacturing Processes for Tissue Engineered Vascular Grafts$967,567
R44 · FY2015 · HL
Novel Manufacturing Processes for Tissue Engineered Vascular Grafts$597,466
R44 · FY2011 · DK
Novel Manufacturing Processes for Tissue Engineered Vascular Grafts$592,354
R44 · FY2012 · DK
IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS ANDTHERAPEUTIC ADVANCES (VITA): BIOENGINEEREDGRAFTS FOR PERIPHERAL VASCULAR DISEASE FOR BASEPERIOD: NOVEMBER 15, 2013 - NOVEMBER 14, 2014$566,202
N01 · FY2015 · HL
IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS ANDTHERAPEUTIC ADVANCES (VITA): BIOENGINEEREDGRAFTS FOR PERIPHERAL VASCULAR DISEASE FOR BASEPERIOD: NOVEMBER 15, 2013 - NOVEMBER 14, 2014$526,284
N01 · FY2014 · HL
IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS ANDTHERAPEUTIC ADVANCES (VITA): BIOENGINEEREDGRAFTS FOR PERIPHERAL VASCULAR DISEASE FOR BASEPERIOD: NOVEMBER 15, 2013 - NOVEMBER 14, 2014$478,270
N01 · FY2016 · HL
Novel Manufacturing Processes for Tissue Engineered Vascular Grafts$236,549
R43 · FY2010 · DK
Thromboresistant Small Diameter Tissue-Engineered Vascular Grafts$217,277
R43 · FY2014 · HL